MX2019015502A - L-asparaginasa modificada. - Google Patents

L-asparaginasa modificada.

Info

Publication number
MX2019015502A
MX2019015502A MX2019015502A MX2019015502A MX2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A
Authority
MX
Mexico
Prior art keywords
modified protein
asparaginase
poly
modified
amino acid
Prior art date
Application number
MX2019015502A
Other languages
English (en)
Spanish (es)
Inventor
Lars Friedrich
Anne O''DONNELL
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17177237.9A external-priority patent/EP3418383A1/en
Priority claimed from US15/671,086 external-priority patent/US10174302B1/en
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2019015502A publication Critical patent/MX2019015502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2019015502A 2017-06-21 2018-06-21 L-asparaginasa modificada. MX2019015502A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762523061P 2017-06-21 2017-06-21
EP17177237.9A EP3418383A1 (en) 2017-06-21 2017-06-21 Modified l-asparaginase
US15/671,086 US10174302B1 (en) 2017-06-21 2017-08-07 Modified L-asparaginase
PCT/EP2018/066647 WO2018234492A1 (en) 2017-06-21 2018-06-21 L-ASPARAGINASE MODIFIED

Publications (1)

Publication Number Publication Date
MX2019015502A true MX2019015502A (es) 2020-07-28

Family

ID=64737515

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015502A MX2019015502A (es) 2017-06-21 2018-06-21 L-asparaginasa modificada.
MX2024015050A MX2024015050A (es) 2017-06-21 2019-12-18 L-asparaginasa modificada

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024015050A MX2024015050A (es) 2017-06-21 2019-12-18 L-asparaginasa modificada

Country Status (15)

Country Link
EP (2) EP3642340B1 (enExample)
JP (2) JP7808424B2 (enExample)
KR (1) KR102727396B1 (enExample)
CN (1) CN111315878B (enExample)
AU (1) AU2018287145B2 (enExample)
BR (1) BR112019027479A2 (enExample)
CA (1) CA3068100A1 (enExample)
DK (1) DK3642340T3 (enExample)
ES (1) ES2979314T3 (enExample)
FI (1) FI3642340T3 (enExample)
IL (1) IL271504B2 (enExample)
MX (2) MX2019015502A (enExample)
SA (2) SA522433360B1 (enExample)
SG (1) SG11201912625QA (enExample)
WO (1) WO2018234492A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7065772B2 (ja) 2015-12-22 2022-05-12 エクスエル‐プロテイン ゲーエムベーハー 低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
ES2979314T3 (es) * 2017-06-21 2024-09-25 Jazz Pharmaceuticals Ireland Ltd L-asparaginasa modificada
EP3713595A1 (en) * 2017-11-22 2020-09-30 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
CA3156066A1 (en) * 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase
KR20230125179A (ko) * 2020-12-23 2023-08-29 재즈 파마슈티칼즈 아일랜드 리미티드 전하-차폐 융합 단백질의 정제 방법
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US20260007728A1 (en) 2022-07-14 2026-01-08 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8519753D0 (en) * 1985-08-06 1985-09-11 Health Lab Service Board Production of 1-asparaginase
GB9017002D0 (en) * 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
WO2007103290A2 (en) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP2851424B1 (en) * 2007-03-09 2016-09-21 Novozymes A/S Thermostable asparaginases
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
DK2571510T3 (en) * 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
ES2979314T3 (es) 2017-06-21 2024-09-25 Jazz Pharmaceuticals Ireland Ltd L-asparaginasa modificada

Also Published As

Publication number Publication date
CN111315878A (zh) 2020-06-19
JP2020528743A (ja) 2020-10-01
AU2018287145B2 (en) 2024-04-18
JP2023081915A (ja) 2023-06-13
EP3642340B1 (en) 2024-03-20
WO2018234492A1 (en) 2018-12-27
RU2020101972A3 (enExample) 2021-11-09
AU2018287145A1 (en) 2020-02-06
RU2020101972A (ru) 2021-07-21
CN111315878B (zh) 2024-04-26
IL271504B1 (en) 2024-01-01
SG11201912625QA (en) 2020-01-30
IL271504B2 (en) 2024-05-01
KR20200030065A (ko) 2020-03-19
EP4180525A1 (en) 2023-05-17
FI3642340T3 (fi) 2024-06-18
BR112019027479A2 (pt) 2020-09-15
KR102727396B1 (ko) 2024-11-08
SA519410870B1 (ar) 2023-03-06
SA522433360B1 (ar) 2024-06-23
MX2024015050A (es) 2025-01-09
JP7808424B2 (ja) 2026-01-29
IL271504A (en) 2020-02-27
JP7770352B2 (ja) 2025-11-14
ES2979314T3 (es) 2024-09-25
DK3642340T3 (da) 2024-06-03
EP3642340A1 (en) 2020-04-29
CA3068100A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
MX2020012332A (es) Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.
MX2023001394A (es) Genes del factor viii optimizados.
EP4467650A3 (en) Scaffold proteins
WO2014202616A3 (en) Rasamsonia gene and use thereof
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2012015139A (es) Polipéptido que tiene o que ayuda en la actividad de degradación del material de carbohidratos y usos del mismo.
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
IN2012DN02981A (enExample)
GB201201178D0 (en) Novel enzymes
PH12013500050A1 (en) Anticancer fusion protein
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
WO2016130628A8 (en) Griffithsin mutants
IN2014DN09963A (enExample)
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
MY167485A (en) Recombinant human interferon-like proteins
AR071534A1 (es) Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa
MY195726A (en) Steviol Glycoside Transport
PH12018500468A1 (en) Fusion protein
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
MY187334A (en) Xylanase
WO2019152418A3 (en) Anti-inflammatory compounds and methods of use